Quantitative proteomic studies addressing unmet clinical needs in sarcoma

Frontiers in Oncology

Oncology

Peter S. Grimison¹  Lisa G. Horvath¹  Phillip J. Robinson²  Roger R. Reddel²  Elizabeth A. Connolly³ 

[1] Department of Medical Oncology, Chris O’Brien Lifehouse, Sydney, NSW, Australia;Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia;ProCan, Children’s Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia;ProCan, Children’s Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia;Department of Medical Oncology, Chris O’Brien Lifehouse, Sydney, NSW, Australia;

关键词: sarcoma;    proteomics;    biomarkers;    drug discovery;    mass spectrometry;   

DOI  :  10.3389/fonc.2023.1126736

 received in 2022-12-18, accepted in 2023-03-31,  发布年份 2023

来源: Frontiers

【 摘 要 】

Sarcoma is a rare and complex disease comprising over 80 malignant subtypes that is frequently characterized by poor prognosis. Challenges in clinical management include uncertainties in diagnosis and disease classification, limited prognostic and predictive biomarkers, incompletely understood disease heterogeneity among and within subtypes, lack of effective treatment options, and limited progress in identifying new drug targets and novel therapeutics. Proteomics refers to the study of the entire complement of proteins expressed in specific cells or tissues. Advances in proteomics have included the development of quantitative mass spectrometry (MS)-based technologies which enable analysis of large numbers of proteins with relatively high throughput, enabling proteomics to be studied on a scale that has not previously been possible. Cellular function is determined by the levels of various proteins and their interactions, so proteomics offers the possibility of new insights into cancer biology. Sarcoma proteomics therefore has the potential to address some of the key current challenges described above, but it is still in its infancy. This review covers key quantitative proteomic sarcoma studies with findings that pertain to clinical utility. Proteomic methodologies that have been applied to human sarcoma research are briefly described, including recent advances in MS-based proteomic technology. We highlight studies that illustrate how proteomics may aid diagnosis and improve disease classification by distinguishing sarcoma histologies and identify distinct profiles within histological subtypes which may aid understanding of disease heterogeneity. We also review studies where proteomics has been applied to identify prognostic, predictive and therapeutic biomarkers. These studies traverse a range of histological subtypes including chordoma, Ewing sarcoma, gastrointestinal stromal tumors, leiomyosarcoma, liposarcoma, malignant peripheral nerve sheath tumors, myxofibrosarcoma, rhabdomyosarcoma, synovial sarcoma, osteosarcoma, and undifferentiated pleomorphic sarcoma. Critical questions and unmet needs in sarcoma which can potentially be addressed with proteomics are outlined.

【 授权许可】

Unknown   
Copyright © 2023 Connolly, Grimison, Horvath, Robinson and Reddel

【 图 表 】

fonc-13-1126736-i001.tif

fonc-13-1126736-i001.tif

fonc-13-1126736-i001.tif

fonc-13-1126736-i001.tif

fonc-13-1126736-i001.tif

fonc-13-1126736-i001.tif

fmed-10-1228833-i0004.tif

fonc-13-1126736-i001.tif

fonc-13-1126736-i001.tif

fonc-13-1126736-i001.tif

fonc-13-1126736-i001.tif

fonc-13-1126736-i001.tif

FPHAR_fphar-2023-1169812_wc_tfx3.tif

FPHAR_fphar-2023-1169812_wc_tfx2.tif

fonc-13-1126736-i001.tif

fonc-13-1126736-i001.tif

fonc-13-1126736-i001.tif

fonc-13-1126736-i001.tif

FMOLB_fmolb-2023-1106128_wc_tfx10.tif

fonc-13-1126736-i001.tif

FMOLB_fmolb-2023-1106128_wc_tfx8.tif

FEART_feart-2023-1169258_wc_tfx18.tif

fonc-13-1126736-i001.tif

FEART_feart-2023-1169258_wc_tfx12.tif

FPHAR_fphar-2023-1202128_wc_tfx5.tif

FPHAR_fphar-2023-1202128_wc_tfx3.tif

fonc-13-1126736-i001.tif

fonc-13-1126736-i001.tif